𝐁𝐞𝐲𝐨𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐚𝐥𝐞: 𝐑𝐞𝐟𝐫𝐚𝐦𝐢𝐧𝐠 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 𝐚𝐬 𝐚 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐃𝐢𝐬𝐞𝐚𝐬𝐞

𝐁𝐞𝐲𝐨𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐚𝐥𝐞: 𝐑𝐞𝐟𝐫𝐚𝐦𝐢𝐧𝐠 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 𝐚𝐬 𝐚 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐃𝐢𝐬𝐞𝐚𝐬𝐞
-By Dr. Madhuresh Kumar Sethi, Pharmaceutical R&D Leader, 70+ Patents, Independent Director
As the Head of Matrix at Mylan Viatris, I’ve come to see obesity as more than a medical challenge—it’s a public health crisis that demands clinical recognition and systemic reform. It’s time we stop viewing obesity as a lifestyle issue and recognize it for what it is: a chronic, relapsing disease.
At the American Peptide Symposium 2025 in San Diego, I highlighted this urgency. While the WHO, US, Canada, Germany, Japan, and the EU have formally classified obesity as a disease, countries like India and the UK still haven’t, despite rising rates of obesity-related disorders.
“When we fail to define a disease, we delay the care people deserve.”
Obesity is linked to over 200 conditions—Type 2 diabetes, hypertension, cardiovascular disease, PCOS, NAFLD, and sleep apnea. This isn’t about appearance—it’s about systemic risk.
“Obesity doesn’t sit on the surface—it roots itself deep within the body’s metabolism.”
That’s where GLP-1 receptor agonists—like Semaglutide and Tirzepatide—come in. These therapies don’t just help with weight—they correct metabolic imbalances. But with popularity comes risk. The market is now flooded with unregulated generics, which, due to their chemical complexity, pose serious safety concerns.
“A peptide isn’t just a product—it’s precision chemistry. And precision demands protection.”
Regulation and medical supervision are non-negotiable.
Of course, medication is just one part of the solution. We must look at metabolic surgery, microbiome therapies, AI-based metabolic tracking, and foundational lifestyle changes.
“No pill can replace purpose. Real change still begins with sleep, food, and stress.”
To me, the goal isn’t weight loss—it’s about restoring health, preventing complications, and improving lives. And none of this can happen without a shift in policy.
“Naming obesity as a disease isn’t a label—it’s a lifeline.”
We must act—because the cost of delay isn’t just clinical, it’s human.
  https://cxolanes.com/exclusive/%f0%9d%90%81%f0%9d%90%9e%f0%9d%90%b2%f0%9d%90%a8%f0%9d%90%a7%f0%9d%90%9d-%f0%9d%90%ad%f0%9d%90%a1%f0%9d%90%9e-%f0%9d%90%92%f0%9d%90%9c%f0%9d%90%9a%f0%9d%90%a5%f0%9d%90%9e-%f0%9d%90%91%f0%9d%90%9e/

Comments

Popular posts from this blog

Gaurav Bayas Appointed as National Sales Manager – Bharat Banking Microfinance (BC Channel) at Axis Bank

Dan Raj appointed as the Head of Sales Development – India at Snowflake

"How CIOs Can Lead AI, Cloud, and ERP Modernization Without Breaking the Business"-By Atin Agarwal